Review of Thyroid Cancer Cases Among Patients with Previous Benign Thyroid Disorders

Thyroid ◽  
2000 ◽  
Vol 10 (8) ◽  
pp. 697-700 ◽  
Author(s):  
Gustav From ◽  
Anders Mellemgaard ◽  
Nils Knudsen ◽  
Torben Jørgensen ◽  
Hans Perrild
Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1959
Author(s):  
Sorina Martin ◽  
Theodor Mustata ◽  
Oana Enache ◽  
Oana Ion ◽  
Andreea Chifulescu ◽  
...  

Background: The primary endpoint was to analyze the preoperatory inflammatory markers and platelet indices in papillary thyroid cancer (PTC) patients compared with patients with benign thyroid pathology. The secondary endpoints were to analyze the relationship between these markers and the pathological features of PTC and to compare their pre- and postoperative levels in PTC patients. Methods: In this retrospective case-control study, we analyzed the files of 1183 patients submitted to thyroidectomy between January 2012 and December 2018. A total of 234 patients with PTC (mean age 51.54 ± 13.10 years, 84.6% females) were compared with an age-, gender- and BMI-matched control group of 108 patients with histologic benign thyroid disorders. Results: PTC patients had higher platelet count (PLT) (p = 0.011), plateletcrit (PCT) (p = 0.006), neutrophil (p = 0.022) and fibrinogen (p = 0.005) levels. Subgroup analysis showed that PTC females had higher PLT (p = 0.006), PCT (p < 0.001) and erythrocyte sedimentation rate (ESR) (p = 0.005), while males had higher neutrophil (p = 0.040) levels. Papillary thyroid cancer patients under 55 years had higher PLT (p < 0.001) and PCT (p = 0.010), while patients over 55 years had higher mean platelet volume (p = 0.032), neutrophil-to-lymphocyte ratio (p = 0.013), ESR (p = 0.005) and fibrinogen (p = 0.019) levels. Preoperative values for platelet indices and inflammatory markers were similar to the postoperative determinations in PTC patients. Fibrinogen (AUROC = 0.602, p = 0.02; cut-off = 327.5 mg/dL, Se = 53.8%, Sp = 62.9%) and PLT (AUROC = 0.584, p = 0.012; cut-off = 223.5 × 103/mm3, Se = 73.1%, Sp = 42.6%) were independent predictors of the presence of PTC. Conclusions: Our data show that fibrinogen and platelet count could be promising, inexpensive, independent predictors for the presence of PTC when compared with benign thyroid disorders.


2014 ◽  
Vol 75 (4) ◽  
pp. 241-246 ◽  
Author(s):  
Delphine Bernard ◽  
Marie Dominique Desruet ◽  
Marianne Wolf ◽  
Julie Roux ◽  
Camille Boin ◽  
...  

2001 ◽  
Vol 25 (3) ◽  
pp. 307-310 ◽  
Author(s):  
Anjali Mishra ◽  
Amit Agarwal ◽  
Gaurav Agarwal ◽  
S.K. Mishra

2019 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Adel Alawady ◽  
Alaal Khalil ◽  
salah abdelaal ◽  
Mohamed Alkilany ◽  
Hassan Ashour

Author(s):  
Nicolas Aide ◽  
Elif Hindié ◽  
Stéphane Bardet ◽  
David Taïeb

2007 ◽  
Vol 12 (4) ◽  
pp. 202-204
Author(s):  
Rajiv Singh ◽  
Mark Aitken

Background: Improvements in health service provision need not be costly and indeed may save money. Administration of radio iodine (131I) to patients with thyrotoxicosis in the UK is often delayed because few endocrinologists have appropriate Administration of Radioactive Substances Advisory Committee (ARSAC) certification. Hence referral must be made to an oncologist. We tried to reduce the time to treatment by acquiring an appropriate licence for an endocrinologist and hence eliminating need for further referral. Methods: An observational study of 414 doses of 131I administered to 353 patients for benign thyroid disorders at a district general hospital by either endocrinologist or oncologist. After decision to treat had been made, the time taken for treatment to be given was compared between the groups. Results: An endocrinologist licensed to prescribe 131I reduced the time taken from referral to administration of 131I from 28 to 12 days ( P < 0.001) compared with oncologists. A further group seen by another endocrinologist and then referred to the licensed endocrinologist also had their delay reduced to 19 days. Treatment was administered within three weeks in 88% of treatments by the endocrinologist, 62% by the non-licensed endocrinologist and only 28% by oncologists. Conclusions: Improving treatment times for patients were achieved at no extra cost and indeed freed up time for oncologists. Encouraging alternative means of delivering services can result in not only better services but also in cost savings. As certification is simple, endocrinologists should be encouraged to deliver 131I themselves rather than devolving care to other practitioners.


2010 ◽  
Vol 31 (3) ◽  
pp. 201-205 ◽  
Author(s):  
Carsten Kobe ◽  
Wolfgang Eschner ◽  
Markus Wild ◽  
Ilka Rahlff ◽  
Ferdinand Sudbrock ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document